Hemogenyx Pharmaceuticals plc
(“Hemogenyx” or the “Company”)
Directorate Change
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that Robin Campbell, Non-Executive Director, will step down from the Board with effect from 5 January 2019.
Dr Campbell became a Director of Hemogenyx in October 2017 and was Chairman during the Company’s listing on the Main Market of the London Stock Exchange. In April 2018 Robin became Non-Executive Director.
Sir Marc Feldmann, Executive Chairman of Hemogenyx, commented:
“I would like to thank Robin for his contribution to the Company, especially during the listing, and for his support as both Chairman and Non-Executive Director. We wish him well in his future endeavors.”
The Company expects to announce a replacement Board appointment in the near future.
Enquiries:
| Hemogenyx Pharmaceuticals Plc | www.hemogenyx.com | |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | Via Walbrook PR | |
| Sir Marc Feldmann, Executive Chairman | ||
| Northland Capital Partners Limited | Tel: +44 (0)20 3861 6625 | |
| Matthew Johnson, Vadim Alexandre, Dugald J Carlean | ||
| Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 | |
| Lucy Williams, Duncan Vasey | ||
| Walbrook PR (UK Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com | |
| Paul McManus | Mob: +44 (0)7980 541 893 | |
| US Media enquiries | ||
| Lowell Goodman | Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, Hemogenyx LLC, located in Brooklyn, New York at its state-of-the-art research facility.
Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
END
BOAGGGAGPUPRGMB